Our findings indicate that combinatorial targeting of CD33/TIM3 or CLL1/TIM3 may enhance therapeutic efficacy without aggravating toxicity in immunotherapy of AML. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.